Antiviral agent 85 

Antiviral agent 85 is a broad-spectrum arenavirus entry inhibitor with an EC₉₀ of 0.13 µM against Junín virus (JUNV). Antiviral agent 85 blocks the entry of various arenaviruses through both hTfR1-dependent and hTfR1-independent pathways, acting on the early and early post-entry stages of infection. Antiviral agent 85 exhibits antiviral activity against a variety of arenaviruses, is well tolerated in hTfR1-expressing JUNV-infected mouse models, but fails to provide protective effects. Antiviral agent 85 can be used in studies related to arenavirus hemorrhagic fevers^[1].

Antiviral agent 85 (Compound 22F) (0.032-100 μM; 3 days) potently inhibits the replication of Junín virus in human lung epithelial A549 cells, with an EC₉₀ of 0.13 μM; it shows no cytotoxicity at concentrations up to 100 μM, with a selectivity index greater than 769^[1].
Antiviral agent 85 (10-50 μM; 16.5 h) inhibits the entry of Machupo virus pseudotyped virus into HEK-293T/T17 cells at a concentration of 10 μM, with an inhibition rate of 70%, and shows no significant cytotoxicity^[1].
Antiviral agent 85 (2-50 μM; 16 h) potently inhibits the entry of multiple pseudotyped arenaviruses into HEK-293T/T17 cells, including hTfR1-dependent Junín virus, Machupo virus and Guanarito virus, hTfR1-independent Tacaribe virus, as well as α-dystroglycan-dependent Lassa virus, with no significant cytotoxicity^[1].
Antiviral agent 85 (50 μM; 3-5 h) inhibits the early stage of Junín virus infection in human lung epithelial cell line A549 when treated at a concentration of 50 μM 1 hour prior to infection. It also reduces viral yield when treated at 2 or 4 hours post-infection, indicating that it exhibits activity in multiple steps associated with viral entry^[1].
Antiviral agent 85 (3-7 d) inhibits the replication of Tacaribe virus in A549 cells with an EC₉₀ of 1.7 μM; it inhibits the replication of the same virus in Vero cells with an EC₉₀ of 3.8 μM; it exhibits only weak activity against Pichindé virus in Vero cells with an EC₉₀ of 12 μM; and shows no activity against the unrelated Rift Valley fever virus^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Antiviral agent 85 (Compound 22F) (5-50 mg/kg; i.p.; once daily; 10 days) does not confer significant protection against JUNV infection in hTfR1 knock-in mice, with survival rates matching or falling below the 50% survival rate of placebo-treated mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

308.42

C₂₀H₂₄N₂O

475595-06-3

O=C(N/N=C/C1=CC=C(C(C)(C)C)C=C1)C2=CC=C(C)C=C2C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wasson SR, et al. Computer-Aided Discovery of Small-Molecule Inhibitors of Pathogenic New World Arenavirus Entry and Replication. ACS Infect Dis. Published online May 4, 2026.  [Content Brief]